OraPharma, Inc. a specialty pharmaceutical company and manufacturer of Arestin® (minocycline HCL 1 mg microspheres), recently launched a completely redesigned version of its Web site www.arestin.com.
According to Senior Product Manager John Lenart, “The site will be unveiled the first week of April and was revamped to provide dental professionals and patients alike with easier, 24/7 access to the most up-to-date information on periodontal disease, which according to the U.S Surgeon General is the second most prevalent disease in the United States.”
For Dental Professionals:
Arestin.com will provide in-depth clinical information on Arestin®, OraPharma’s locally administered antibiotic indicated as an adjunct to scaling and root planing for the treatment of adult periodontal disease. With the site’s new and improved navigation capabilities, viewers will find many useful Arestin and periodontal topics including :
- Streaming video demonstration instructions
- Benefits of microsphere technology
- In-depth clinical and safety profile
- Secure Online ordering
- Complete Prescribing information
- Downloadable banners
For Patients:
With many consumers conducting their health-related research online, OraPharma designed the site to provide easy access to periodontal disease diagnosis and treatment information with just a few mouse clicks. Consumer-friendly topics currently posted include the following:
- What are periodontal diseases?
- What are the symptoms?
- Periodontal maintenance
- About Arestin®
- Frequently asked questions
In addition, the patient section of the www.arestin.com site includes a wealth of educational tools such as:
- An oral health self-evaluation test
- A glossary of oral health terms
- Important links and other online resources
“Our intent is to establish www.arestin.com as the leading online destination for patients and dental professionals alike who seek the latest information on the diagnosis, risks and treatment of periodontal disease,” said Lenart.
About Arestin®
Arestin is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. Arestin may be used as part of a periodontal maintenance program which includes good oral hygiene, and scaling and root planing.
About OraPharma, Inc.
OraPharma, Inc., a specialty pharmaceutical company in the emerging field of oral health care, discovers, develops and commercializes therapeutics for oral health care. OraPharma's initial product, Arestin®, which represents a promising therapeutic advance for the adjunct treatment of periodontal disease, was approved for marketing by the FDA in February 2001 and launched on April 2, 2001. Currently OraPharma, Inc. distributes: Arestin, Ultracet, Oraqix, and promotes Reach Access, and ACT X-2.